--- title: "ImmuneOnco Completes Key Patient Enrollment in Phase III Trial of Lead Cancer Drug IMM01" type: "News" locale: "en" url: "https://longbridge.com/en/news/280085467.md" description: "ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has completed enrollment of 133 patients for the interim analysis of its Phase III trial of IMM01 (Timdarpacept) for chronic myelomonocytic leukemia. The drug has received orphan-drug designation from the FDA and aims to enhance anti-tumor activity while maintaining safety. Successful trial results could strengthen ImmuneOnco's position in the immuno-oncology market. The latest analyst rating for the stock (HK:1541) is a Hold with a price target of HK$4.50." datetime: "2026-03-22T22:37:25.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280085467.md) - [en](https://longbridge.com/en/news/280085467.md) - [zh-HK](https://longbridge.com/zh-HK/news/280085467.md) --- # ImmuneOnco Completes Key Patient Enrollment in Phase III Trial of Lead Cancer Drug IMM01 ### Claim 70% Off TipRanks Premium - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) just unveiled an update. ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has completed enrollment of 133 patients for the interim analysis of its Phase III clinical trial of IMM01 (Timdarpacept) as a first-line treatment for chronic myelomonocytic leukemia. The trial builds on prior recognition of IMM01, which in combination with azacitidine has received orphan-drug designation from the U.S. Food and Drug Administration for this indication. IMM01 (Timdarpacept) is engineered to block the CD47 “don’t eat me” signal while engaging Fc-gamma receptors to enhance macrophage-mediated anti-tumor activity, and its design avoids binding to human red blood cells, supporting a favorable safety profile. Successful progress in this late-stage study could strengthen ImmuneOnco’s position in the global immuno-oncology market and enhance the value of its patent-protected CD47-targeting platform for patients and investors, although clinical and commercialization risks remain. The most recent analyst rating on (HK:1541) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H stock, see the HK:1541 Stock Forecast page. **More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H** ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a China-based biopharmaceutical company focused on innovative immuno-oncology therapies. Its core product, IMM01 (Timdarpacept), is a first-in-class SIRPα-Fc fusion protein targeting CD47, designed to activate macrophages and treat hematologic malignancies such as chronic myelomonocytic leukemia, with global intellectual property and commercial rights held by the group. **Average Trading Volume:** 1,723,080 **Technical Sentiment Signal:** Sell **Current Market Cap:** HK$3.86B ### Related Stocks - [516820.CN](https://longbridge.com/en/quote/516820.CN.md) - [516930.CN](https://longbridge.com/en/quote/516930.CN.md) - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) - [588250.CN](https://longbridge.com/en/quote/588250.CN.md) - [512010.CN](https://longbridge.com/en/quote/512010.CN.md) - [588860.CN](https://longbridge.com/en/quote/588860.CN.md) - [01541.HK](https://longbridge.com/en/quote/01541.HK.md) - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) - [588130.CN](https://longbridge.com/en/quote/588130.CN.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) - [516500.CN](https://longbridge.com/en/quote/516500.CN.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [510660.CN](https://longbridge.com/en/quote/510660.CN.md) - [159859.CN](https://longbridge.com/en/quote/159859.CN.md) - [560600.CN](https://longbridge.com/en/quote/560600.CN.md) - [159102.CN](https://longbridge.com/en/quote/159102.CN.md) ## Related News & Research - [CStone’s CS2009 Posts Strong ASCO Data as Company Prepares Global Phase III Trial](https://longbridge.com/en/news/288238438.md) - [Akeso lung cancer drug helps patients live 15% longer than immunotherapy in China trial](https://longbridge.com/en/news/288172168.md) - [Leads Biolabs R&D Symposium: Platform Synergy and Multi-Mechanism Integration Reshape the Immuno-Oncology Landscape](https://longbridge.com/en/news/285930281.md) - [Nanjing Leads Biolabs Showcases Promising Opamtistomig Data Ahead of 2026 Lung Cancer Summit](https://longbridge.com/en/news/287858670.md) - [Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026 | SMMT Stock News](https://longbridge.com/en/news/288144694.md)